AYTUHIGH SIGNALFINANCIAL10-K

AYTU conducted a major equity raise of $16.6 million in June 2025 while recording an $8.3 million impairment to product technology rights, signaling both liquidity needs and asset quality concerns.

The combination of a substantial equity raise through prefunded warrants and a significant intangible asset impairment suggests the company is addressing both immediate capital needs and acknowledging overvalued assets on its balance sheet. The timing of these events in June 2025 indicates management took decisive action to strengthen the balance sheet while cleaning up asset valuations.

Comparing 2025-09-23 vs 2024-09-26View on EDGAR →
FINANCIAL ANALYSIS

AYTU's financial profile shows mixed signals with cash position strengthening to $31.0 million (+54.7%) supported by the equity raise, while operating performance deteriorated with SG&A expenses substantially higher and gross profit declining 16% to $45.8 million. The company meaningfully reduced R&D spending and saw operating losses widen, though the improved cash position and reduced intangible asset base following the impairment provide a cleaner foundation going forward.

FINANCIAL STATEMENT CHANGES
SG&A Expense
P&L
+84.3%
$18.9M→$34.8M

SG&A up 84.3% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Cash & Equivalents
Balance Sheet
+54.7%
$20.0M→$31.0M

Cash position surged 54.7% — strong cash generation or capital raise providing significant financial cushion.

R&D Expense
P&L
-52.5%
$2.8M→$1.3M

R&D spending cut 52.5% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
-49%
-$5.3M→-$7.8M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Operating Cash Flow
Cash Flow
-39.6%
-$1.4M→-$1.9M

Operating cash flow fell 39.6% — earnings quality concerns; investigate working capital changes and non-cash items.

Accounts Receivable
Balance Sheet
+31.9%
$23.6M→$31.2M

Receivables surged 31.9% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Stockholders Equity
Balance Sheet
-31.6%
$27.7M→$19.0M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Capital Expenditure
Cash Flow
-30.7%
$329K→$228K

Capex reduced 30.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Assets
Balance Sheet
+27.9%
$61.9M→$79.2M

Current assets grew 27.9% — improving short-term liquidity or inventory/receivables build.

Gross Profit
P&L
-16%
$54.6M→$45.8M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

LANGUAGE CHANGES
NEW — 2025-09-23
PRIOR — 2024-09-26
ADDED
Each of these prefunded warrants is exercisable at any time for one share of the Company s common stock on a one-for-one basis under the terms of the agreements between the Company and the investors.
The number of warrants, excluding prefunded warrants, outstanding as of June 30, 2024, is comprised of 3,821,115 liability classified warrants and 18,114 equity classified warrants.
Relates to the June 2025 issuance of 8,233,332 prefunded warrants at a public offering price of $1.4999 to purchase 8,233,332 shares of the Company s common stock at an exercise price of $0.0001 per share (the June 2025 Prefunded Warrants ).
In June 2025, the Company recorded an impairment to its product technology rights intangible asset of $8.3 million.
Accordingly, $19.1 million of gross carrying amount and $10.8 million of related accumulated amortization have been removed from this table as of June 30, 2025.
In June 2025, the Company raised gross proceeds of $16.6 million from the issuance of the June 2025 Common Stock the June 2025 Prefunded Warrants.
The June 2025 Prefunded Warrants may be exercised on a one-for-one basis at any time subject to certain limitations as defined in the agreements between the Company and the investors.
The June 2025 Prefunded Warrants had a fair value of approximately $12.3 million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholders equity in the Company s consolidated financial statements.
There was $1.3 million of issuance costs allocated to the June 2025 Prefunded Warrants, which were recorded in other (expense) income in the consolidated statement of operations.
See Note 12 - Fair Value Measurements and Note 14 - Stockholders Equity for further detail.
REMOVED
The warrants issued during fiscal 2024 were a result of 1,806,434 Tranche B Warrants being exercise to 1,806,434 Tranche B Pre-Funded Warrants.
Expense associated with the wind down of the Consumer Health Segment is related to the Consumer Health Segment.
Expense associated with the closure of the Grand Prairie, Texas manufacturing site is related to the Rx Segment.
The number of warrants outstanding as of June 30, 2023, is comprised of 6,068,763 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants and 39,072 equity classified warrants.
Expense associated with severance and employee benefits and exit and disposal activities are included in restructuring costs in the consolidated statements of operations.
The number of warrants outstanding as of June 30, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,806,434 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants.
As pre-funded warrants do not have an expiration date, they have been excluded from the calculation of the weighted average remaining contractual life in years.
Expense associated with inventory write-downs is recorded in cost of sales in the consolidated statements of operations.
As of September 16, 2024, there were 6,148,993 shares of common stock outstanding.
Solely for convenience, our trademarks and tradenames referred to in this Form 10-K may appear without the or symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights to these trademarks and tradenames We obtained statistical data, market and product data, and forecasts used throughout this Form 10-K from market research, publicly available information and industry publications.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →